From: Apolipoproteins and the risk of giant cell arteritis—a nested case–control study
Adjusted for BMI | Adjusted for physical activity | Adjusted for BMI and physical activity | ||||
---|---|---|---|---|---|---|
OR | 95% CI | OR | 95% CI | OR | 95% CI | |
All | ||||||
ApoA1 | 1.50 | 1.12–2.02 | 1.57 | 1.17–2.10 | 1.48 | 1.09–1.99 |
ApoB | 1.01 | 0.76–1.35 | 1.04 | 0.78–1.40 | 1.08 | 0.81–1.46 |
ApoB/ApoA1 | 0.84 | 0.62–1.13 | 0.83 | 0.62–1.12 | 0.90 | 0.66–1.22 |
Women | ||||||
ApoA1 | 1.66 | 1.19–2.31 | 1.81 | 1.31–2.51 | 1.67 | 1.20–2.34 |
ApoB | 1.18 | 0.86–1.62 | 1.15 | 0.83–1.58 | 1.22 | 0.88–1.69 |
ApoB/ApoA1 | 0.90 | 0.63–1.27 | 0.92 | 0.58–1.15 | 0.91 | 0.64–1.30 |
Men | ||||||
ApoA1 | 0.90 | 0.44–1.84 | 0.71 | 0.21–1.59 | 0.70 | 0.31–1.61 |
ApoB | 0.47 | 0.21–1.07 | 0.61 | 0.28–1.33 | 0.60 | 0.27–1.33 |
ApoB/ApoA1 | 0.70 | 0.37–1.32 | 0.87 | 0.47–1.63 | 0.86 | 0.46–1.64 |